Jason M. Broderick

Patients with breast cancer and macrometastases who omitted axillary lymph node dissection experienced noninferior survival compared with those who didn't.

Enfortumab vedotin plus pembrolizumab demonstrated a median OS of 33.6 months in patients with first-line metastatic urothelial carcinoma.

“MajesTEC-9 is the second phase 3 study to show a significant PFS and OS benefit in the second-line setting and beyond with teclistamab-based therapy for RRMM,” said Roberto Mina, MD.

“This study is important in that it represents a potential therapy option for patients in resource-limited parts of the world," said Glenn J. Hanna, MD.

Data from the phase 3 LIBRETTO-432 study may support adjuvant selpercatinib as a new standard of care in this NSCLC population.

Draxonrasib yielded a 13.2 month OS vs 6.6 months with chemotherapy for patients with metastatic PDAC.

Triple-oral metronomic chemotherapy plus nivolumab elicited a median OS of 10.32 months in this head and neck squamous cell carcinoma population.

"Early molecular testing is critically important now in these mCSPC patients,” said TALAPRO-3 lead investigator Neeraj Agarwal, MD.

Data from the EMERALD-3 trial may position the STRIDE regimen with or without lenvatinib as a compelling therapeutic option in this HCC population.

A review of top ASCO abstracts with the potential to change everyday oncology practice.